NASDAQ:SPHS - Sophiris Bio Stock Price, Forecast & News

Sophiris Bio trades on the NASDAQ under the ticker symbol "SPHS."

Sophiris Bio Inc (NASDAQ:SPHS) posted its quarterly earnings results on Friday, November, 8th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.07). View Sophiris Bio's Earnings History.

Sophiris Bio is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Sophiris Bio.

3 brokerages have issued 12-month price objectives for Sophiris Bio's shares. Their forecasts range from $2.80 to $6.00. On average, they expect Sophiris Bio's share price to reach $4.60 in the next twelve months. This suggests a possible upside of 601.4% from the stock's current price. View Analyst Price Targets for Sophiris Bio.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sophiris Bio in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sophiris Bio.

News stories about SPHS stock have been trending positive recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Sophiris Bio earned a coverage optimism score of 3.0 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Sophiris Bio.

Some companies that are related to Sophiris Bio include ASLAN PHARMACEU/ADR (ASLN), Enlivex Therapeutics (ENLV), Catalyst Biosciences (CBIO), Elite Pharmaceuticals (ELTP), ESSA Pharma (EPIX), Catabasis Pharmaceuticals (CATB), IMMUTEP LTD/S (IMMP), Aclaris Therapeutics (ACRS), Trevena (TRVN), Eyenovia (EYEN), CTI BioPharma (CTIC), Oncolytics Biotech (ONCY), Trillium Therapeutics (TRIL), Cumberland Pharmaceuticals (CPIX) and Neos Therapeutics (NEOS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Sophiris Bio investors own include Sarepta Therapeutics (SRPT), Intercept Pharmaceuticals (ICPT), Celator Pharmaceuticals (CPXX), SLS International (SLS), Anavex Life Sciences (AVXL), Heat Biologics (HTBX), Verastem (VSTM), Advanced Micro Devices (AMD), Synergy Pharmaceuticals (SGYP) and Novavax (NVAX).

Sophiris Bio's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Wedbush Securities Inc. (0.26%). View Institutional Ownership Trends for Sophiris Bio.

SPHS stock was purchased by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. View Insider Buying and Selling for Sophiris Bio.

Shares of SPHS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SPHS stock can currently be purchased for approximately $0.66.

Sophiris Bio has a market capitalization of $22.61 million. The biopharmaceutical company earns $-6,780,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Sophiris Bio employs 6 workers across the globe.View Additional Information About Sophiris Bio.

The official website for Sophiris Bio is http://www.sophirisbio.com/.

Sophiris Bio's mailing address is 1258 PROSPECT STREET, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-777-1760 or via email at [email protected]